CCR study reveals how leukemia chemotherapy drug Ara-C damages neurons causing balance problems
Summary
CCR scientists led by Andre Nussenzweig have discovered why the chemotherapy drug Ara-C (used to treat blood cancers) causes movement and balance problems in some patients. The research, published in Nature on June 25, 2025, reveals that Ara-C causes highly disruptive DNA damage in specific neurons in the brain. The study also found that a related drug called gemcitabine causes less severe DNA damage to neurons, suggesting a potentially safer alternative.
Source
Twitter / XCCR study reveals how leukemia chemotherapy drug Ara-C damages neurons causing balance problemsgo.nih.govKey quotes
· 3 pulledNew research from CCR scientists explains why some neurons in the brain are impaired by Ara-C, a chemotherapy drug used to treat blood cancers, which results in movement and balance problems for some patients.
Led by Andre Nussenzweig, Ph.D., Chief of the Laboratory of Genome Integrity, the researchers have learned how Ara-C causes highly disruptive DNA damage in neurons and which brain cells are most vulnerable to the drug.
Their study, reported June 25, 2025, in Nature, also found that damage to DNA is less severe when neurons are exposed to a related drug called gemcitabine.
You might also wanna read
Anti-aging drug combo dasatinib+quercetin causes brain damage in mice, study finds
A study from the University of Connecticut published in PNAS found that the dasatinib+quercetin (D+Q) drug combination, widely studied for a
Human iPSC-derived sensory neuron platform identifies STE20 kinase inhibitors as neuroprotectants against chemotherapy-induced peripheral neuropathy
This article presents a novel high-throughput screening platform using human iPSC-derived sensory neurons to identify neuroprotective compou
UCLA discovers first stroke rehabilitation drug to repair brain damage
Senolytic treatment linked to oligodendrocyte dysfunction and demyelination in brain study
This scientific research article investigates the effects of senolytic treatment (dasatinib and quercetin combination) on the corpus callosu
pnas.org·24d ago
Brazilian Researchers Develop Polylaminin Drug That May Reverse Spinal Cord Injuries
Brazilian researchers have developed a groundbreaking drug called polylaminin, derived from placental protein laminin, that shows promise in
www1.folha.uol.com.br·9mo ago
Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
A new experimental pill called daraxonrasib has shown promising results in extending survival for patients with advanced pancreatic cancer.
cnbc.com·24d agoComments
Sign in to join the conversation.
No comments yet. Be the first.